Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18623761 | COMPACTABLE ORAL FORMULATIONS OF IBUTAMOREN | April 2024 | June 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18416354 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | January 2024 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18542163 | PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAM | December 2023 | February 2025 | Allow | 14 | 2 | 0 | Yes | Yes |
| 18238303 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | August 2023 | December 2024 | Abandon | 15 | 1 | 1 | No | No |
| 18323040 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | May 2023 | April 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18317654 | Compositions Containing Dofetilide and Mexiletine and Uses Thereof | May 2023 | September 2024 | Allow | 16 | 2 | 1 | Yes | No |
| 18132545 | LIQUID PHARMACEUTICAL FORMULATION | April 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18190060 | CO-CRYSTAL COMPOUNDS COMPRISING LITHIUM IONS AND ISONICOTINAMIDE | March 2023 | November 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18119806 | IN SITU TREATMENT OF SEED IN FURROW | March 2023 | September 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18176204 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | February 2023 | October 2024 | Abandon | 20 | 3 | 0 | Yes | No |
| 18110581 | COMPOSITION COMPRISING CINNAMALDEHYDE AND ZINC TO IMPROVE SWALLOWING | February 2023 | May 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18110202 | FORMULATIONS OF VASOPRESSIN | February 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18106659 | NANOPARTICLE COMPOSITIONS COMPRISING CANNABINOIDS | February 2023 | May 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18057941 | COMPACTABLE ORAL FORMULATIONS OF IBUTAMOREN | November 2022 | March 2024 | Allow | 26 | 3 | 0 | Yes | No |
| 17999321 | COMPOSITIONS COMPRISING ORGANO-SILANOL COMPOUNDS, AND APPLICATIONS | November 2022 | June 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17926267 | A TOPICAL ANTIMICROBIAL COMPOSITION | November 2022 | July 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17970192 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | October 2022 | January 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17967783 | LINEZOLID FORMULATIONS | October 2022 | April 2025 | Abandon | 30 | 2 | 1 | Yes | Yes |
| 17966148 | Composition For Surface Modification | October 2022 | March 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 17941384 | METHOD FOR DELIVERING INSULIN | September 2022 | January 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 17930713 | LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTS | September 2022 | December 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17929461 | METHODS USING PHOSPHATIDYLSERINE POWDER | September 2022 | February 2025 | Abandon | 29 | 3 | 0 | No | No |
| 17865734 | SOLID ORAL DOSAGE FORM OF IRINOTECAN FOR THE TREATMENT OF CANCER | July 2022 | February 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 17850854 | COMBINATION PRODUCTS OF TOBRAMYCIN COMPOUNDS AND DEXAMETHASONE COMPOUNDS | June 2022 | November 2024 | Abandon | 29 | 4 | 0 | No | No |
| 17834809 | POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF | June 2022 | February 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17746647 | Antipsychotic Injectable Depot Composition | May 2022 | April 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17744713 | ENDOPHYTIC FALCIPHORA ORYZAE FO-R20 AND ITS APPLICATION | May 2022 | April 2025 | Allow | 35 | 2 | 1 | No | No |
| 17725772 | PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAM | April 2022 | June 2024 | Abandon | 26 | 4 | 1 | Yes | No |
| 17721742 | METHODS FOR PREVENTION AND TREATMENT OF FIBROMYALGIA BY CONTACT VASODILATORS | April 2022 | September 2023 | Abandon | 17 | 1 | 1 | No | No |
| 17719686 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | April 2022 | May 2025 | Allow | 37 | 2 | 0 | No | No |
| 17698537 | PHARMACEUTICAL COMPOSITIONS OF BORTEZOMIB | March 2022 | April 2024 | Abandon | 25 | 5 | 0 | No | No |
| 17675780 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | February 2022 | May 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17672927 | Antipsychotic Injectable Depot Composition | February 2022 | April 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17669595 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | February 2022 | October 2023 | Abandon | 20 | 2 | 1 | Yes | No |
| 17584553 | FORMULATIONS INCLUDING DIHYDROHONOKIOL | January 2022 | September 2023 | Abandon | 20 | 2 | 1 | No | No |
| 17630403 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | January 2022 | March 2025 | Allow | 37 | 1 | 1 | No | No |
| 17577170 | Antipsychotic Injectable Depot Composition | January 2022 | May 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17423210 | Parenteral Pharmaceutical Composition Comprising Azacitidine or Decitabine in DMSO | December 2021 | November 2023 | Abandon | 28 | 4 | 0 | No | No |
| 17527928 | MEDICAMENT CONTAINING MODIFIED STARCH FOR THE TREATMENT OF ANASTOMOSES | November 2021 | July 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17594373 | BACTERICIDAL AGENT FOR AGRICULTURAL OR HORTICULTURAL USE, PLANT DISEASE CONTROL METHOD, AND PRODUCT FOR PLANT DISEASE CONTROL USE | October 2021 | August 2024 | Allow | 34 | 5 | 1 | Yes | No |
| 17498514 | Risperidone or Paliperidone Implant Formulation | October 2021 | March 2025 | Allow | 41 | 1 | 0 | No | No |
| 17470471 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | September 2021 | August 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17465062 | HAND SANITIZERS WITH IMPROVED AESTHETICS AND SKIN-CONDITIONING TO ENCOURAGE COMPLIANCE WITH HAND HYGIENE GUIDELINES | September 2021 | February 2024 | Allow | 29 | 3 | 0 | Yes | No |
| 17412189 | Natural Concentrated Composition for Killing and Repelling Pests | August 2021 | August 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17405462 | Foaming Topical Antimicrobial Cleaning Compositions | August 2021 | December 2024 | Abandon | 40 | 4 | 0 | Yes | No |
| 17424321 | METHODS FOR TREATING SCHIZOPHRENIA | July 2021 | March 2025 | Abandon | 44 | 3 | 0 | No | No |
| 17378458 | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | July 2021 | October 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17423378 | Drug Delivery System | July 2021 | June 2025 | Abandon | 47 | 3 | 1 | Yes | No |
| 17368367 | PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAM | July 2021 | February 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17364469 | LONG-ACTING INJECTION DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTS | June 2021 | December 2022 | Allow | 18 | 2 | 0 | Yes | No |
| 17304578 | Cleansing Compositions | June 2021 | November 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17340594 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | June 2021 | June 2024 | Abandon | 37 | 1 | 1 | Yes | No |
| 17327703 | COMBINATION PRODUCTS OF TOBRAMYCIN COMPOUNDS AND DEXAMETHASONE COMPOUNDS | May 2021 | March 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17318586 | AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE | May 2021 | March 2025 | Allow | 46 | 4 | 0 | Yes | Yes |
| 17314330 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | May 2021 | October 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17289768 | COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND PLANT GROWTH REGULATORS | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17231761 | FORMULATION BASED ON VITAMIN E OR AN ESTER THEREOF FOR TREATING BACTERIAL AND FUNGAL BIOFILMS | April 2021 | June 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17227940 | ANTIBACTERIAL NANOFIBER | April 2021 | October 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 17204183 | PACLITAXEL-HYALURONIC ACID CONJUGATE IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER | March 2021 | January 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17273828 | SUSTAINED-RELEASE INJECTABLE ANTIBIOTICAL FORMULATION | March 2021 | August 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17182425 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING RESPIRATORY VIRAL INFECTIONS USING GREEN TREE EXTRACT | February 2021 | February 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17267917 | COMPOSITION OF MICRONUTRIENTS AND ORGANIC COMPOUNDS FOR TREATING, COATING AND ENCRUSTING SEEDS | February 2021 | October 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17172771 | INJECTABLE COMPOSITION WITH AROMATASE INHIBITOR | February 2021 | November 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 17104337 | Methods for the Preparation of Injectable Depot Compositions | November 2020 | April 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17074619 | Radiation-Sterilized Biodegradable Drug Delivery Compositions | October 2020 | June 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17067187 | REDUCED VOLUME FORMULATIONS INCLUDING AMINO ACID ENTITIES | October 2020 | December 2023 | Abandon | 38 | 1 | 1 | No | No |
| 17045325 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS | October 2020 | April 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16948832 | NOVEL ARTIFICIAL TEARS CONTAINING RECOMBINANT HUMAN LYSOZYME AND RECOMBINANT HUMAN EGF | October 2020 | February 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17042795 | LIQUID PHARMACEUTICAL FORMULATION | September 2020 | December 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 17032934 | ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE | September 2020 | March 2021 | Allow | 5 | 0 | 0 | Yes | No |
| 17032882 | ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE | September 2020 | September 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 17033019 | ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE | September 2020 | March 2021 | Allow | 6 | 0 | 0 | Yes | No |
| 17032585 | Foaming Topical Antimicrobial Cleaning Compositions | September 2020 | July 2024 | Abandon | 46 | 4 | 0 | Yes | No |
| 17021739 | PREPARATION OF THERAPEUTIC FOAM | September 2020 | November 2021 | Allow | 14 | 0 | 0 | Yes | No |
| 16980204 | IMMUNOREGULATORY ROLE OF 3-OH-KYNURENAMINE AND USES THEREOF | September 2020 | March 2023 | Allow | 30 | 0 | 1 | Yes | No |
| 17009702 | ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE | September 2020 | January 2021 | Allow | 5 | 0 | 0 | Yes | No |
| 16993017 | AQUEOUS FORMULATION FOR INSOLUBLE DRUGS | August 2020 | October 2022 | Allow | 26 | 3 | 0 | Yes | No |
| 16967993 | EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67 | August 2020 | January 2025 | Abandon | 53 | 1 | 1 | Yes | No |
| 16967411 | LIQUID COMPOSITIONS OF APREPITANT | August 2020 | August 2024 | Abandon | 49 | 3 | 1 | Yes | No |
| 16945985 | METHOD OF PREPARING CONDITIONER FOR PROTECTED AGRICULTURE ACIDIC SOIL WITH DISTILLERS' GRAINS AND USE | August 2020 | February 2025 | Abandon | 54 | 3 | 1 | No | No |
| 16944639 | POWDER COATING COMPOSITIONS FOR COATING PHARMACEUTICAL PELLETS | July 2020 | March 2023 | Abandon | 32 | 2 | 0 | Yes | No |
| 16945053 | PENETRATING PAIN RELIEF CREAM | July 2020 | May 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 16934807 | PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONS | July 2020 | March 2022 | Allow | 19 | 2 | 1 | Yes | No |
| 16924529 | Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof | July 2020 | September 2023 | Abandon | 38 | 2 | 0 | No | Yes |
| 16920556 | CATIONIC LIPIDS AND TRANSFECTION METHODS | July 2020 | March 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 16959979 | PACLITAXEL-HYALURONIC ACID CONJUGATE IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER | July 2020 | July 2021 | Abandon | 13 | 1 | 0 | No | No |
| 16959657 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF AMINOSALICYLATES | July 2020 | May 2025 | Abandon | 59 | 3 | 1 | No | No |
| 16909197 | Composition For Surface Modification | June 2020 | August 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16956631 | NOVEL FORMULATIONS OF VASOPRESSIN | June 2020 | March 2023 | Abandon | 33 | 3 | 0 | No | No |
| 16892550 | Cannabinoids and Pearl Powder Topical | June 2020 | March 2023 | Abandon | 34 | 2 | 0 | No | No |
| 16767706 | LIQUID FORMULATIONS OF RILUZOLE FOR ORAL AND INTRAVENOUS USE | May 2020 | July 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16881277 | RISPERIDONE-CONTAINING MICROCAPSULE, METHOD FOR PREPARING SAME AND RELEASE CONTROL METHOD | May 2020 | April 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16764468 | LINEZOLID FORMULATIONS | May 2020 | July 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16868307 | SOLID DISPERSION OF RIFAXIMIN | May 2020 | May 2024 | Abandon | 48 | 2 | 0 | No | No |
| 16868013 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | May 2020 | May 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16760736 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION | April 2020 | April 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16760595 | EXTERNAL PREPARATION FOR TREATING TRICHOPHYTOSIS UNGUIUM | April 2020 | May 2023 | Allow | 37 | 1 | 1 | No | No |
| 16860373 | METHOD OF PROVIDING HIGH STABILITY NON-IONIC N-VINYL BUTYROLACTAM IODINE | April 2020 | October 2024 | Abandon | 53 | 4 | 1 | Yes | No |
| 16859628 | TOPICAL FORMULATION CONTAINING PAPAVERINE AND SILDENAFIL AND USES THEREOF | April 2020 | May 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16758272 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | April 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PEEBLES, KATHERINE.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PEEBLES, KATHERINE works in Art Unit 1617 and has examined 499 patent applications in our dataset. With an allowance rate of 38.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner PEEBLES, KATHERINE's allowance rate of 38.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PEEBLES, KATHERINE receive 2.85 office actions before reaching final disposition. This places the examiner in the 93% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PEEBLES, KATHERINE is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +52.9% benefit to allowance rate for applications examined by PEEBLES, KATHERINE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.1% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 10.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 22% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 53.1% of appeals filed. This is in the 19% percentile among all examiners. Of these withdrawals, 41.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.